참고문헌
- Balsara BR, Pei J, Mitsuuchi Y, et al (2004). Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis, 25, 2053-9. https://doi.org/10.1093/carcin/bgh226
- Cappuzzo F, Tallini G, Finocchiaro G, et al (2010). Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol, 21, 562-7. https://doi.org/10.1093/annonc/mdp357
- Caron E, Ghosh S, Matsuoka Y, et al (2010). A comprehensive map of the mTOR signaling network. Mol Syst Biol, 6, 453.
- Dowling RJ, Pollak M, Sonenberg N (2009). Current status and challenges associated with targeting mTOR for cancer therapy. Bio Drugs, 23, 77-91.
- Dowling RJ, Topisirovic I, Alain T, et al (2010). mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science, 328, 1172-6. https://doi.org/10.1126/science.1187532
- Dziadziuszko R, Merrick DT, Witta SE, et al (2010). Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol, 28, 2174-80. https://doi.org/10.1200/JCO.2009.24.6611
- Efeyan A, Sabatini DM (2010). mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol, 22, 169-76. https://doi.org/10.1016/j.ceb.2009.10.007
- Guertin DA, Guntur KV, Bell GW, et al (2006). Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol, 16, 958-70. https://doi.org/10.1016/j.cub.2006.03.084
- Heitman J, Movva NR, Hall MN (1991). Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science, 253, 905-9. https://doi.org/10.1126/science.1715094
- Iwanaga K, Yang Y, Raso MG, et al (2008). Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res, 68, 1119-27. https://doi.org/10.1158/0008-5472.CAN-07-3117
- Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics, 2007. CA Cancer J Clin, 57, 43-66. https://doi.org/10.3322/canjclin.57.1.43
- Jiang BH, Liu LZ (2009). PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res, 102, 19-65. https://doi.org/10.1016/S0065-230X(09)02002-8
- Milton DT, Riely GJ, Azzoli CG, et al (2007). Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer, 110, 599-605. https://doi.org/10.1002/cncr.22816
- Pfister DG, Johnson DH, Azzoli CG, et al (2004). American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol, 22, 330-53.
- Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28. https://doi.org/10.1038/nrc2536
- Price KA, Azzoli CG, Krug LM, et al (2010). Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol, 5, 1623-9. https://doi.org/10.1097/JTO.0b013e3181ec1531
- Quek R, Wang Q, Morgan JA, et al (2011). Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res, 17, 871-9. https://doi.org/10.1158/1078-0432.CCR-10-2621
- Schmid K, Bago-Horvath Z, Berger W, et al (2010). Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer, 103, 622-8. https://doi.org/10.1038/sj.bjc.6605761
- Shaw RJ, Cantley LC (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424-30. https://doi.org/10.1038/nature04869
- Steck PA, Pershouse MA, Jasser SA, et al (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15, 356-62. https://doi.org/10.1038/ng0497-356
- Tang JM, He QY, Guo RX, Chang XJ (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer, 51, 181-91. https://doi.org/10.1016/j.lungcan.2005.10.003
- Tarhini A, Kotsakis A, Gooding W, et al (2010). Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res, 16, 5900-7. https://doi.org/10.1158/1078-0432.CCR-10-0802
- Wang X, Beugnet A, Murakami M, et al (2005). Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol, 25, 2558-72. https://doi.org/10.1128/MCB.25.7.2558-2572.2005
- Witzig TE, Reeder CB, LaPlant BR, et al (2011). A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia, 25, 341-7. https://doi.org/10.1038/leu.2010.226
- Yuan R, Kay A, Berg WJ, Lebwohl D (2009). Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol, 2, 45. https://doi.org/10.1186/1756-8722-2-45
피인용 문헌
- Analysis of ICU Treatment on Resection of Giant Tumors in the Mediastinum of the Thoracic Cavity vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3843